Sanofi Entered into a License Agreement with Terran Biosciences for Two Late-Stage CNS pipeline Assets to Treat Neurological and Psychiatric Indications
Shots:
- Sanofi to receive an upfront & are eligible to receive success-based milestones along with royalties
- Terran to get WW exclusive rights to develop & commercialize in all fields of use & will advance the development of two P-III CNS therapeutics for neurological and psychiatric indications including multiple novel applications
- Additionally, Terran has built a CNS-focused, tech-enabled drug development platform and continues to advance the no. of late-stage assets including novel psychedelic-based therapeutics
Ref: PR Newswire | Image: Sanofi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
